Featured Publications
Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients
Baraban E, Hu S, Hui P, Podoltsev N, Cooper D, Xu M. Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplantation 2016, 52: 634-637. PMID: 27991892, DOI: 10.1038/bmt.2016.332.Peer-Reviewed Original ResearchExpression of CD30 as a biomarker to predict response to brentuximab vedotin
Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.Peer-Reviewed Original ResearchEpithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping
Xu ML, Yang B, Carcangiu ML, Hui P. Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping. Modern Pathology 2008, 22: 232-238. PMID: 18820674, DOI: 10.1038/modpathol.2008.165.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarcinoma, Squamous CellComparative Genomic HybridizationDiagnosis, DifferentialEndometrial NeoplasmsEpithelioid CellsFemaleGene Expression Regulation, NeoplasticGenetic TestingGenotypeGestational Trophoblastic DiseaseHumansItalyLung NeoplasmsMiddle AgedPregnancyUnited StatesUterine Cervical NeoplasmsConceptsEpithelioid trophoblastic tumorTrophoblastic tumorSquamous cell carcinomaUterine cervixComparative genomic hybridizationCommon squamous cell carcinomaChromosomal alterationsInvasive squamous cell carcinomaChorionic-type intermediate trophoblastGestational trophoblastic diseaseGenomic hybridizationDNA genotypingIntermediate trophoblastTrophoblastic diseaseAnatomic locationComparative genomic hybridization analysisTrophoblastic originTumorsGenomic hybridization analysisCervixNormal tissuesTrophoblastic natureConventional comparative genomic hybridizationCarcinomaChromosomal profileDendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma
Pelland K, Mathews S, Kamath A, Cohen P, Hudnall SD, Cotta CV, Xu ML. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma. Applied Immunohistochemistry & Molecular Morphology 2018, 26: e101-e106. PMID: 29189264, DOI: 10.1097/pai.0000000000000615.Peer-Reviewed Original ResearchConceptsPrimary mediastinal large B-cell lymphomaMediastinal gray zone lymphomaClassic Hodgkin lymphomaGray zone lymphomaPD-L1Mediastinal large B-cell lymphomaLarge B-cell lymphomaDendritic cell markersB-cell lymphomaCell gene expression profilesHodgkin's lymphomaRare entityCD123LymphomaTherapeutic potentialCell markersTherapeutic significanceGenetic featuresGene expression profilesFascinRepresentative sectionsExpression profilesImmunohistochemistryTumorsDiagnosis
2024
Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results
Mata D, Lee J, Shanmugam V, Marcus C, Schrock A, Williams E, Ritterhouse L, Hickman R, Janovitz T, Patel N, Kroger B, Ross J, Mirza K, Oxnard G, Vergilio J, Elvin J, Benhamida J, Decker B, Xu M. Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology 2024, 84: 1224-1237. PMID: 38422618, DOI: 10.1111/his.15168.Peer-Reviewed Original ResearchConceptsNon-Hodgkin's lymphomaPlasma-cell neoplasmsAcute myeloid leukemiaCirculating tumor DNAHodgkin lymphomaMyelodysplastic syndromeHaematopoietic neoplasmsNext-generation sequencingTissue-based NGSMaximum somatic allele frequencyFoundationOne Liquid CDxTherapy-resistant clonesRelevant genomic alterationsPositive percent agreementPotential clinical utilityLymphoid malignanciesTumor DNAMyeloid leukemiaPlasma-cellsTissue biopsiesGenomic alterationsPathogenic alterationsLiquid biopsyMolecular profilingTP53
2022
Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature
Matsumoto NP, Yuan J, Wang J, Shen Q, Chen X, Kim Y, Zuppan CW, Chang CC, Cui W, Chen D, Shi M, Gisriel SD, Chen M, Xu ML, Pan Z. Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature. Modern Pathology 2022, 35: 865-874. PMID: 35105959, DOI: 10.1038/s41379-022-01014-w.Peer-Reviewed Original ResearchConceptsMast cell sarcomaConcurrent systemic mastocytosisMast cell activation symptomsGerm cell tumorsSerum tryptase levelsMast cell tryptaseMast cell growthImmunophenotypic overlapMedian followReactive eosinophilsReview of literatureMedian ageCell sarcomaRare entitySystemic mastocytosisTherapeutic regimensTryptase levelsCell tumorsCommon siteImmunohistochemical stainingKIT D816VVariable positivityRare formPatientsActivation symptoms
2021
Coronavirus Disease 2019 (COVID-19) Coronary Vascular Thrombosis Correlation with Neutrophil but Not Endothelial Activation
Johnson JE, McGuone D, Xu ML, Jane-Wit D, Mitchell RN, Libby P, Pober JS. Coronavirus Disease 2019 (COVID-19) Coronary Vascular Thrombosis Correlation with Neutrophil but Not Endothelial Activation. American Journal Of Pathology 2021, 192: 112-120. PMID: 34599881, PMCID: PMC8479934, DOI: 10.1016/j.ajpath.2021.09.004.Peer-Reviewed Original ResearchConceptsVascular cell adhesion molecule-1Intracellular adhesion molecule-1Adhesion molecule-1Von Willebrand factorEndothelial activationMolecule-1Severe coronavirus disease 2019Neutrophil extracellular trap formationCell adhesion molecule-1COVID-19 cohortCOVID-19 patientsNeutrophil-platelet aggregatesCoronavirus disease 2019Extracellular trap formationCOVID-19Transcription factor p65Extensive thrombosisLymphocytic infiltrationMyocardial injuryThrombotic diathesisInflammatory activationNeutrophil activationCardiovascular diseaseDisease 2019Autopsy tissueSecondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients
Gru AA, Bacchi CE, Pulitzer M, Bhagat G, Kempf W, Robson A, Plaza JA, Pincus L, Raghavan S, Xu M, da Silva T, Salavaggione AL, Subtil A, Battistella M. Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients. Journal Of Cutaneous Pathology 2021, 48: 1367-1378. PMID: 34089205, PMCID: PMC9555338, DOI: 10.1111/cup.14077.Peer-Reviewed Original ResearchConceptsClassic Hodgkin lymphomaSecondary skin involvementHodgkin's lymphomaCutaneous involvementSkin involvementComprehensive histopathologic evaluationStage IV diseaseNodular sclerosis typeLarge case seriesBoard-certified dermatopathologistClassic HLSkin disseminationMixed cellularityMost patientsCase seriesSclerosis typeImmunophenotypic featuresInfiltrative plaquesFirst diagnosisHistopathologic evaluationMultiple lesionsSkin lesionsSingle lesionLarge seriesClinical diagnosisIRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias
Katz SG, Edappallath S, Xu ML. IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias. The American Journal Of Surgical Pathology 2021, 45: 1391-1398. PMID: 34172624, DOI: 10.1097/pas.0000000000001765.Peer-Reviewed Original ResearchConceptsChronic myelomonocytic leukemiaAcute monocytic leukemiaBlast countCore biopsyMyelomonocytic leukemiaBone marrowPredictive valueMonocytic leukemiaBone marrow core biopsiesCases of AMoLMarrow core biopsiesAcute myeloid leukemia subtypesExpression of IRF8Acute myeloid leukemiaTrephine core biopsiesReliable surface markersDendritic cell progenitorsNegative predictive valuePositive predictive valuePotential biomarker candidatesBlast increaseMonocytic blastsUseful immunostainsBlast percentageReactive monocytosisCombined liver–cytokine humanization comes to the rescue of circulating human red blood cells
Song Y, Shan L, Gbyli R, Liu W, Strowig T, Patel A, Fu X, Wang X, Xu ML, Gao Y, Qin A, Bruscia EM, Tebaldi T, Biancon G, Mamillapalli P, Urbonas D, Eynon E, Gonzalez DG, Chen J, Krause DS, Alderman J, Halene S, Flavell RA. Combined liver–cytokine humanization comes to the rescue of circulating human red blood cells. Science 2021, 371: 1019-1025. PMID: 33674488, PMCID: PMC8292008, DOI: 10.1126/science.abe2485.Peer-Reviewed Original ResearchConceptsRed blood cellsBlood cellsHuman sickle cell diseaseSickle cell diseaseImmunodeficient murine modelKupffer cell densityBone marrow failureMISTRG miceIntrasplenic injectionSCD pathologyCell diseaseMurine modelComplement C3RBC survivalVivo modelHuman cytokinesPreclinical testingHematopoietic stem cellsHuman red blood cellsMarrow failureFumarylacetoacetate hydrolase geneHuman erythropoiesisHuman liverHuman hepatocytesMiceClinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group
Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moser KA, Bhattacharya S, Xu M, Babu D, Foucar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber DA, Hasserjian RP. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology 2021, 34: 1358-1366. PMID: 33526873, DOI: 10.1038/s41379-021-00739-4.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAcute undifferentiated leukemiaWhite blood cellsLymphoblastic leukemiaAcute leukemiaBone Marrow Pathology GroupHigher white blood cellEvent-free survivalNatural killer cellsClinical outcome dataNative immune systemMore frequent expressionAUL patientsFree survivalAmbiguous lineageOverall survivalCytoplasmic CD3Leukemia groupClinical presentationHLA-DRKiller cellsPlatelet countProvisional entityCD10 expressionMyeloid leukemia
2020
Cutaneous Involvement in Plasma Cell Myeloma
Panse G, Subtil A, McNiff JM, Glusac EJ, Ko CJ, Galan A, Myung P, Xu ML. Cutaneous Involvement in Plasma Cell Myeloma. American Journal Of Clinical Pathology 2020, 155: 106-116. PMID: 32885235, DOI: 10.1093/ajcp/aqaa122.Peer-Reviewed Original ResearchConceptsPlasma cell myelomaCutaneous involvementSquamous cell carcinomaAmyloid depositionCell carcinomaCell myelomaCases of PCMBone marrow involvementCyclin D1 immunoreactivityDisease-related deathLight chain restrictionCCND1 gene rearrangementMarrow involvementSkin involvementClinicopathologic featuresCytomorphologic spectrumCutaneous lesionsPoor outcomeCommon immunophenotypeChain restrictionClinical dataCytogenetic findingsOlder individualsGene rearrangementsMyelomaDisease-associated CTNNBL1 mutation impairs somatic hypermutation by decreasing nuclear AID
Kuhny M, Forbes LR, Çakan E, Vega-Loza A, Kostiuk V, Dinesh RK, Glauzy S, Stray-Pedersen A, Pezzi AE, Hanson IC, Vargas-Hernandez A, Xu ML, Akdemir Z, Jhangiani SN, Muzny DM, Gibbs RA, Lupski JR, Chinn IK, Schatz DG, Orange JS, Meffre E. Disease-associated CTNNBL1 mutation impairs somatic hypermutation by decreasing nuclear AID. Journal Of Clinical Investigation 2020, 130: 4411-4422. PMID: 32484799, PMCID: PMC7410074, DOI: 10.1172/jci131297.Peer-Reviewed Original ResearchConceptsB cellsActivation-induced cytidine deaminaseHealthy donor counterpartsIsotype-switched B cellsCommon variable immunodeficiencyMemory B cellsSomatic hypermutationAutoimmune cytopeniasDecreased incidenceVariable immunodeficiencyB cell linesUnderlying molecular defectsNuclear AIDPatient's EBVRamos B cellsPatientsProtein 1Cell linesMolecular defectsCellsCytidine deaminaseMutationsGlucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy
Nair S, Bar N, Xu ML, Dhodapkar M, Mistry PK. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Molecular Genetics And Metabolism 2020, 129: 286-291. PMID: 32044242, PMCID: PMC8223251, DOI: 10.1016/j.ymgme.2020.01.009.Peer-Reviewed Original ResearchConceptsGaucher disease type 1Monoclonal gammopathyAntigenic targetsClonal immunoglobulinDisease type 1B cell activationAccumulation of glucosylceramideGD1 patientsImmunogenic lipidsMetabolic inflammationMultiple myelomaGD patientsHigh riskTarget antigenCell activationImmunoglobulin typeGammopathyType 1PatientsGenetic deficiencyAge-related phenotypesSaposin CClonal IgLysosomal glucocerebrosidaseGlcSph
2019
Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma
Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, Xu ML. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Human Pathology 2019, 93: 54-64. PMID: 31425695, PMCID: PMC7038910, DOI: 10.1016/j.humpath.2019.08.008.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaCell lymphomaAnn Arbor stage IIINovel independent prognostic factorAggressive B-cell lymphomasHigh Bim expressionAverage patient ageBim expressionIndependent prognostic factorLarge academic medical centerKi-67 indexNovel prognostic markerB-cell lymphomaAcademic medical centerCyclin D1 overexpressionHuman mantle cell lymphomaMCL cohortMIPI scoreProgressive diseaseComplete responseOverall survivalPatient agePrognostic factorsTumor cell survivalFemale ratioPhiladelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia
Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia. American Journal Of Hematology 2019, 94: e256-e259. PMID: 31273842, DOI: 10.1002/ajh.25571.Peer-Reviewed Original ResearchAbnormal KaryotypeAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBlast CrisisBone MarrowChromosome AberrationsDiagnosis, DifferentialDiagnostic ErrorsFemaleFollow-Up StudiesHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesNeoplasms, Second PrimaryPhiladelphia ChromosomeRetrospective StudiesYoung AdultClinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx
Chen PH, Yang Y, O'Malley DP, Xu ML. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Annals Of Diagnostic Pathology 2019, 41: 129-135. PMID: 31247533, DOI: 10.1016/j.anndiagpath.2019.06.007.Peer-Reviewed Original ResearchConceptsB-cell non-Hodgkin lymphomaEBV-negative casesAggressive B-NHLPD-L1Peptide receptor radionuclide therapyAggressive B-cell lymphomasEBV-positive DLBCLEBV-positive patientsDisease-free intervalPrimary clinical outcomeYear of diagnosisEBV-positive casesReceptor radionuclide therapyExpression of SSTR2Non-Hodgkin lymphomaExpression of CD30Five yearsAvailable outcome dataB-cell lymphomaEBV negativityInitial therapyClinicopathologic characteristicsBetter prognosisCase seriesClinical outcomesMantle Cell Lymphoma With Mantle Zone Growth Pattern
Yuan J, Li S, Liu X, Su RJ, Chen M, Wu X, Zheng G, Smith LM, Wang L, Li Y, Liu C, Zhou J, Shen Q, Zhang L, Wang E, Xu ML, Pan Z. Mantle Cell Lymphoma With Mantle Zone Growth Pattern. American Journal Of Clinical Pathology 2019, 152: 132-145. PMID: 31140550, DOI: 10.1093/ajcp/aqz043.Peer-Reviewed Original ResearchConceptsMantle zone growth patternMantle cell lymphomaCell lymphomaHigher clinical stageOverall survivalPathologic featuresClinicopathologic dataClinical stageSuspicious morphologyClinical significanceCyclin D1Lymphoma cellsCell cytologyGrowth patternSignificant differencesPatientsLymphomaChemotherapyLymphCD5ImmunostainsCytologyCasesClinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances 2019, 3: 1540-1545. PMID: 31085507, PMCID: PMC6517660, DOI: 10.1182/bloodadvances.2019000090.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleHumansMaleMiddle AgedMutationMyelodysplastic SyndromesNuclear ProteinsNucleophosminPrognosisProportional Hazards ModelsProtein Tyrosine Phosphatase, Non-Receptor Type 11Survival RateTumor Suppressor Protein p53ConceptsMyelodysplastic syndromeMyeloid neoplasmsDe novo acute myeloid leukemia (AML) patientsNovo acute myeloid leukemia patientsAcute myeloid leukemia patientsBone marrow blastsAggressive clinical courseStem cell transplantLimited case seriesShorter overall survivalMyeloid leukemia patientsIntensive therapeutic regimensTotal mutation countsMarrow blastsOverall survivalClinical courseCase seriesCell transplantMultivariable analysisTherapeutic regimensLeukemia patientsLarge cohortYounger agePatientsNormal karyotypeAllogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations
Shallis RM, Gleeson S, Azar M, Malinis M, Xu ML, Seropian SE, Gowda L, Zeidan AM. Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. Leukemia & Lymphoma 2019, 60: 2584-2587. PMID: 30943051, DOI: 10.1080/10428194.2019.1594221.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements